** Shares of drug developer Checkpoint Therapeutics CKPT.O rise 8.9% to $4 in premarket trading
** The U.S. FDA, on Friday, approved company's drug for treatment of a type of cancer of the outer layer of the skin
** The drug to be marketed under the brand name Unloxcyt is the company's first drug that has received approval
** Unloxcyt is part of a class of drugs, PD-L1 antibody, which works by binding to a protein called programmed death-ligand 1 that helps the body's immune system in killing cancer cells
** Company said it is "currently developing a commercial launch plan" for the drug
** Up to last close, stock up 60.3% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。